Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 10:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–14 of 14 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Deep to Moderate NMB Clear all
Completed Phase 4 Interventional Results available

Safety of Sugammadex for the Reversal of Neuromuscular Blockade in American Society of Anesthesiologists (ASA) Class 3 or 4 Participants (MK-8616-145)

NCT03346057
View directory record Official record
Conditions
Reversal of Neuromuscular Blockade
Interventions
Sugammadex 2 mg/kg, Sugammadex 4 mg/kg, Sugammadex 16 mg/kg, Neostigmine + Glycopyrrolate, Rocuronium, Vecuronium
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
20
States / cities
Birmingham, Alabama • Tucson, Arizona • Loma Linda, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2020 · Synced Sep 5, 2026, 10:05 AM EDT
Completed Phase 4 Interventional Results available

Efficacy, Safety, and Pharmacokinetics of Sugammadex for Reversal of Neuromuscular Blockade (NMB) in Pediatric Participants (MK-8616-089)

NCT03351608
View directory record Official record
Conditions
Neuromuscular Blockade
Interventions
Sugammadex 2 mg/kg, Sugammadex 4 mg/kg, Neostigmine + Glycopyrrolate, Neostigmine + Atropine
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
2 Years to 16 Years
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
11
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2021 · Synced Sep 5, 2026, 10:05 AM EDT
Withdrawn Phase 2 Interventional

Pilot RCT of Therapeutic Hypothermia Plus Neuromuscular Blockade in COVID-19 Patients With ARDS

NCT03376854
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult, Sars-CoV2
Interventions
Hypothermia, Neuromuscular Blocking Agents, Standard of Care
Device · Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 29, 2021 · Synced Sep 5, 2026, 10:05 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Prospective Randomized Trial of Moderate vs Deep Neuromuscular Blockade During Laparoscopic Ventral Hernia Repair

NCT03201744
View directory record Official record
Conditions
Hernia, Ventral, Neuromuscular Blockade, Pneumoperitoneum
Interventions
Patients will be randomized to moderate (TOF 1-2) or deep (post tetanic count 1-2) relaxation. Low pressure insufflation (start pressure set at 8 mm Hg)
Procedure
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Sep 5, 2026, 10:05 AM EDT
Completed Phase 4 Interventional Results available

Deep Versus Moderate Neuromuscular Blockade During Laparoscopic Surgery

NCT02812186
View directory record Official record
Conditions
Cholecystitis, Endometriosis, Bowel Obstruction, Fibroids, Prostate Cancer, Chronic Kidney Disease, Uterine Prolapse
Interventions
Deep to Moderate NMB, Moderate to Deep NMB, Rocuronium
Procedure · Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Apr 7, 2020 · Synced Sep 5, 2026, 10:05 AM EDT
Completed Phase 4 Interventional Results available

Efficacy and Safety of Sugammadex Dosed According to Actual Body Weight (ABW) or Ideal Body Weight (IBW) in Reversal of Neuromuscular Blockade (NMB) in Morbidly Obese Participants (MK-8616-146)

NCT03346070
View directory record Official record
Conditions
Neuromuscular Blockade
Interventions
Sugammadex 2 mg/kg ABW, Sugammadex 2 mg/kg IBW, Sugammadex 4 mg/kg ABW, Sugammadex 4 mg/kg IBW, Neostigmine + Glycopyrrolate, Rocuronium or Vecuronium
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
13
States / cities
Sacramento, California • Miami, Florida • Kansas City, Kansas + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Sep 5, 2026, 10:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Hemodynamic and Respiratory Variations During Laparoscopic Surgery With and Without Deep Neuromuscular Blockade.

NCT02025075
View directory record Official record
Conditions
Intraoperative Complications, Postoperative Complications, Laparoscopy, Surgical Complications From General Anesthesia, Ventilator-Induced Lung Injury
Interventions
Rocuronium
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 5, 2026, 10:05 AM EDT
Completed Phase 4 Interventional Results available

Neuromuscular Blockade on Shoulder Pain of Elderly

NCT03210376
View directory record Official record
Conditions
Malignant Neoplasms of Digestive Organs, Malignant Neoplasms of Female Genital Organs, Malignant Neoplasms of Male Genital Organs, Malignant Neoplasms of Urinary Tract
Interventions
Deep Neuromuscular Blockade (NMB), Moderate Neuromuscular Blockade (NMB), Sugammadex, Neostigmine, Pain Assessment
Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
65 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 24, 2020 · Synced Sep 5, 2026, 10:05 AM EDT
Active, not recruiting Phase 2 Interventional Results available

The Effect of Deep Versus Moderate Muscle Relaxants in Men During and After Robotic Surgery for Prostate Cancer

NCT03808077
View directory record Official record
Conditions
Prostate Cancer
Interventions
Rocuronium 0.3mg/kg/hr, Rocuronium 1.5mg/kg/hr
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 80 Years · Male only
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Sep 5, 2026, 10:05 AM EDT
Completed Phase 4 Interventional Results available

Surgical Conditions During Laparoscopic Bariatric Surgery

NCT02703909
View directory record Official record
Conditions
Morbid Obesity
Interventions
Rocuronium, Insufflation pressure
Drug · Device
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 20, 2018 · Synced Sep 5, 2026, 10:05 AM EDT
Completed Phase 4 Interventional Results available

Does Deep Neuromuscular Blockade Improve Operating Conditions During Total Hip Replacements?

NCT03219294
View directory record Official record
Conditions
Arthropathy of Hip
Interventions
Vecuronium 0.1 mg/kg, Vecuronium 0.2mg/kg
Drug
Lead sponsor
Craig Curry
Other
Eligibility
50 Years to 75 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Portland, Maine
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced Sep 5, 2026, 10:05 AM EDT
Withdrawn Phase 4 Interventional

Does Depth of Neuromuscular Blockade (NMB) Affect Surgical Conditions in Obese Patients Undergoing Robotic Surgery

NCT03591289
View directory record Official record
Conditions
GYN Disorders, Urologic Diseases
Interventions
NMB with rocuronium bromide
Drug
Lead sponsor
Rainer Lenhardt
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 20, 2021 · Synced Sep 5, 2026, 10:05 AM EDT
Recruiting Not applicable Interventional

Low Pressure Pneumoperitoneum and Postoperative Ileus

NCT05344417
View directory record Official record
Conditions
Postoperative Ileus, Gastrointestinal Dysfunction
Interventions
Pneumoperitoneum Pressure, Neuromuscular blockade, Pneumoperitoneum insufflation device, Neuromuscular blockade reversal
Procedure · Device · Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 2, 2025 · Synced Sep 5, 2026, 10:05 AM EDT
Completed Phase 4 Interventional Results available

Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616) for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to <2 Years (MK-8616-169)

NCT03909165
View directory record Official record
Conditions
Neuromuscular Blockade
Interventions
Sugammadex 2 mg/kg, Sugammadex 4 mg/kg, Neostigmine + Glycopyrrolate, Neostigmine + Atropine
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
1 Day to 2 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
7
States / cities
Palo Alto, California • Miami, Florida • Oklahoma City, Oklahoma + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2025 · Synced Sep 5, 2026, 10:05 AM EDT